Logo Valence
Populaire
Se connecter
Loading data for OCUL — first visit, this takes a few seconds.

Ajouter à la liste de suivi

Ocular Therapeutix Inc.

NasdaqGM: OCUL · Prix en temps réel · USD
11.73
+0.72 (6.54%)
À la clôture : Aug 20, 2026, 8:00 PM

Le cours, les chiffres clés et les dernières actualités, au même endroit.

Ocular Therapeutix Inc. (OCUL) : cours, analyse et données

6.54%

Aucune donnée disponible

Cours acheteur6.26
Capitalisation boursière2.44B
Chiffre d’affaires (ttm)52.05M
Résultat net (ttm)-301.45M
0.94
-1.4
n/a
-7.63
P/B (ttm)4.68
P/S (ttm)46.79
Date des résultatsn/a
Cours vendeur10.89
Volume2,965,797
Volume moy. (20D)2,701,922
Ouverture11.29
Clôture précédente11.01
Fourchette du jour11.19 - 11.74
Intervalle de 52 semaines6.23 - 16.44
Analysten/a
Objectif de prixn/a
Dividendesn/a
Date ex-dividenden/a

À propos de OCUL

Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing...

[En savoir plus]
Industrie Biotechnology
Secteur Healthcare
Date d’introduction Jul 25, 2014
Employés 325
Bourse NasdaqGM
Symbole boursier OCUL
Site web https://www.ocutx.com
Profil complet de l’entreprise

Performance financière

En 2025, le chiffre d’affaires de Ocular Therapeutix s’élevait à 51.95M, soit une baisse de -18.47% par rapport aux 63.72M de l’année précédente. Le bénéfice s’élevait à -265.94M, soit une hausse de 37.43%.

États financiers
news image

1 semaine il y a · Stocktwits

OCUL, FDMT Stock Clock Best Day In Weeks After EyePoint’s Trial Setback — Here’s Why

EyePoint Pharmaceuticals said on Monday that its late-stage trial of DURAVYU, an experimental long-lasting eye implant for wet age-related macular degeneration, missed its main goal.

news image

1 semaine il y a · Stocktwits

EYPT Stock On Track To Hit 16-Month Lows After Wet AMD Trial Setback – Retail Sees Ocular Therapeutics As A Better Buyout Candidate

EyePoint posted the results for its Phase 3 Lugano trial, which compared its Duravyu therapy with Aflibercept, the standard treatment for wet AMD.

news image

3 semaines il y a · MT Newswires

Ocular Therapeutix's NDA Plans for Axpaxli in Wet AMD Remain on Track, RBC Says

Ocular Therapeutix's (OCUL) regulatory plans for Axpaxli in wet age-related macular degeneration rem

news image

3 semaines il y a · StockStory

3 Healthcare Stocks with Questionable Fundamentals

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have not only realized strong financial performance bu...

news image

3 semaines il y a · Stocktwits

OCUL Stock In Spotlight After Q2 Loss Comes In Narrower Than Estimated – A Look At Key Highlights

Ocular’s total cash and cash equivalents stood at $598.6 million at the end of the second quarter, which it expects will provide sufficient cash runway until 2028.

Page 1 de 2